Trial results for a study investigating mental health associations with Vitiligo were posted on ClinicalTrials.gov on 2025-12-02, involving 36,104 participants.
Background
Vitiligo is a chronic autoimmune skin condition characterized by depigmented patches. Beyond its visible dermatological impact, vitiligo can significantly affect a patient's quality of life, leading to psychological distress, social stigma, and emotional burden. Understanding the prevalence and risk of comorbid mental health conditions, such as depression and anxiety, in individuals with vitiligo is crucial for providing comprehensive patient care. This study aimed to quantify these risks within a large population, considering potential variations across different ethnicities.
Trial design
This completed cohort study, titled "Mental Health Associations With Vitiligo," enrolled 36,104 participants in the UK. The study investigated the risks of comorbid mental health conditions in adults with vitiligo compared to controls. Conditions examined included Vitiligo, Depressive Episode, Recurrent Depressive Disorder, Anxiety Disorders, and Social Phobia. The primary objective was to determine the risks of these mental health conditions and to evaluate if relative risks varied by ethnicity.
Key results
The study reported several key measurements regarding mental health conditions in participants:
- Number of Participants With Depressive Episodes:
- Cases (with Vitiligo): 1018 participants
- Controls: 4007 participants
- Risk of Depressive Episodes Within Adult Patients With Vitiligo:
- Cases (with Vitiligo): 157 participants
- Controls (reference group): 501 participants
- Number of Participants With Anxiety Disorder:
- Cases (with Vitiligo): 569 participants
- Controls: 2031 participants
- Number of Participants With Recurrent Depressive Disorder:
- Cases (with Vitiligo): 1093 participants
- Controls: 4305 participants
- Risk of Anxiety Disorder Within Adult Patients With Vitiligo:
- Cases (with Vitiligo): 122 participants
- Controls (reference group): 382 participants
- Risk of Recurrent Depressive Disorder Within Adult Patients With Vitilgo:
- Cases (with Vitiligo): 113 participants
- Controls (reference group): 312 participants
Key analyses also reported the following hazard ratios:
- A Hazard Ratio (HR) of 1.11 (95.0% CI: 0.92-1.32) was observed.
- Another Hazard Ratio (HR) of 1.23 (95.0% CI: 1.01-1.51) was observed.
- A third Hazard Ratio (HR) of 1.25 (95.0% CI: 1.01-1.56) was observed.
What this means
The results from this large cohort study highlight a significant association between vitiligo and an increased risk of certain mental health conditions, including depressive episodes, anxiety disorders, and recurrent depressive disorder. The reported hazard ratios suggest that individuals with vitiligo may face an elevated likelihood of experiencing these psychological comorbidities. These findings underscore the importance for clinicians to consider the mental health burden in patients with vitiligo and to integrate psychological screening and support into their care plans, recognizing that the impact of vitiligo extends beyond its dermatological manifestations.
Source
The information regarding these trial results was obtained from ClinicalTrials.gov, a public database of clinical studies. The results for the study NCT04953338, titled "Mental Health Associations With Vitiligo", were posted on 2025-12-02 on clinicaltrials.gov.